2015 Archived Content
According to the Centers for Disease Control and Prevention, antibiotic-resistant infections are associated with an additional 23,000 deaths and 2 million illnesses in the United States each year. The estimated annual impact of antibiotic-resistant infections on the national economy is $20 billion in excess direct health care costs, and as much as $35 billion in lost productivity from hospitalizations and sick days. By holding the Re-Entering Antibacterial Drug Development Summit, we at Cambridge Healthtech Institute are trying to contribute to the efforts to revive antibacterial pipeline, and to improve antimicrobial stewardship in the United States and worldwide. This Summit is designed as a forum for knowledge and opinion exchange between the major stakeholders, who are shaping the current state of antibacterial discovery and development.
Novel Monoclonal Antibodies for the Prevention and Treatment of Bacterial Infections.
Steven J. Projan. Ph.D., Senior Vice President, R&D, Innovative Medicines unit, Head of Infectious Diseases & Vaccines, Medimmune
Antibiotic Adjuvants To Reclaim Legacy Drugs
Gerard D. Wright, Ph.D., Director, Michael DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University, Canada Research Chair in Molecular Studies of Antibiotics
Bringing The Full Power Of Chemical Synthesis To Bear On The Discovery Of New Antibiotics
Andrew G. Myers. Ph.D., Amory Houghton Professor of Chemistry, Department of Chemistry & Chemical Biology, Harvard University
Gram-Negative Antibiotics: The Importance Of Compound Properties For Drug Discovery
Heinz E. Moser, Ph.D., Executive Director – Chemistry Infectious Diseases, Global Discovery Chemistry, Novartis Institutes for BioMedical Research
View Full Agenda
Overcoming The Challenges Of Developing New Antibiotics For Resistant Bacteria With Regulatory Support And New Diagnostics
Barry Eisenstein, M.D., FACP, FIDSA, FAAM, Distinguished Physician, Antimicrobials, Merck & Co., Inc.
Achieving Value and Improving Patient Safety Through Innovative Methods of Antimicrobial Utilization - Experience At the Front Line of Care
Ronald G. Nahass, M.D., MHCM, President, ID Care
The Economics of Modern Anti-Infectives
Rene Russo, PharmD, Chief Development Officer, Arsanis, Inc.
View Full Agenda
Latest Advances in Pathogen Detection
Kimberly E. Hanson, M.D., Medical Director, Mycology, Mycobacteriology, and Virology Laboratories, Section Chief, Microbiology, ARUP Laboratories
The Role Of The Microbiology Laboratory In Antimicrobial Stewardship Programs
Joint Presentation:
Karen C. Carroll, M.D., Director, Division of Microbiology, Department of Pathology, The John Hopkins Hospital
Edina Avdic, Pharm.D., MBA, Clinical Specialist, Infectious Diseases, Associate Director, Antimicrobial Stewardship Program, The John Hopkins Hospital
View Full Agenda
For more details on the conference, please contact:
Marina Filshtinsky, M.D.
Senior Director, Conferences
Cambridge Healthtech Institute
Phone: 781-972-5496
Email: mfilshtinsky@healthtech.com
For exhibit & sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-972-5412, Fax: (781) 972-5470
email: cbenton@healthtech.com